{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007514","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-10-01T11:45:14+00:00","discovered_at":"2026-10-01T11:50:00.291893+00:00","generated_at":"2026-10-12T14:15:29.098591+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Valion Bio completes oral mucosal Entolimod formulation work with Shear Kershman Laboratories","bullets":["Valion Bio and Shear Kershman Laboratories completed formulation work for an oral mucosal Entolimod using SKL's BioViscid drug-delivery platform.","The program is a potential second, needle-free pathway alongside Valion's injectable Entolimod; next study will test measurable systemic exposure to Entolimod.","Valion estimates U.S. doses for oral mucosal Entolimod could be 10 to 40 times its injectable program, assuming supply to ~2.0M military, 1.0M firefighters and 790,000 law enforcement officers.","Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod for acute radiation syndrome and radiation-induced neutropenia.","The release says all FDA-approved products address only hematopoietic ARS, and no treatment is approved for the gastrointestinal indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007514","json":"https://secwatch.observer/filing/0001683168-26-007514.json","markdown":"https://secwatch.observer/filing/0001683168-26-007514.md","text":"https://secwatch.observer/filing/0001683168-26-007514.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/0001683168-26-007514-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/valion_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T14:15:29.098591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}